Pharmacyclics Announces Six Xcytrin Abstracts to Be Presented at ASTRO Annual Meeting Next Week
... company`s pivotal 429-patient Phase III clinical trial of Xcytrin for the potential treatment of brain metastases.......That study will report on the strong correlation between tumor size and neurocognitive function, further validating one of the study`s two co-primary endpoints....... highlight Xcytrin`s potential utility in glioblastoma multiforme (i.e., GBM or primary brain tumors) and further elucidate Xcytrin`s unique mechanism of action....
Nov 02 7:30 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/011102/sff011_1.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines